This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

20/20 GeneSystems (TWTG) Stock Overview

Develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. More details

TWTG fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Shares are highly illiquid

Does not have a meaningful market cap ($17M)

TWTG Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW482,450 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

482,450 investors already sharing narratives

View all narratives

20/20 GeneSystems Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for 20/20 GeneSystems
Historical stock prices
Current Share Price	US$3.50
52 Week High	US$7.00
52 Week Low	US$3.20
Beta	0
1 Month Change	0%
3 Month Change	0%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-50.00%

Recent updates

Shareholder Returns

	TWTG	US Medical Equipment	US Market
7D	0%	-6.0%	0.2%
1Y	n/a	-21.7%	19.6%

Return vs Industry: Insufficient data to determine how TWTG performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how TWTG performed against the US Market.

Price Volatility

Is TWTG's price volatile compared to industry and market?
TWTG volatility
TWTG Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	8.4%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.2%

Stable Share Price: TWTG has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine TWTG's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2000	n/a	Jonathan Cohen	2020biolabs.com

20/20 GeneSystems Inc., a clinical laboratory testing company, develops and commercializes artificial intelligence powered cancer screenings tests for the earlier detection of multiple cancers. It offers OneTest, a multi-cancer screening test to identify types cancer, including lung, liver, and pancreas; PAULA’s Test, a blood test for the early detection of lung cancer; BioCheck, a suspicious powder screening kit that provides a screening tool to determine whether a powder contains biological material to check common substances that cause powder incidents; and CoronaCheck Tests, a suite of Covid-19 detection tests. The company was formerly known as 20/20 Gene Systems, Inc. and changed its name to 20/20 GeneSystems Inc. in June 2001.

20/20 GeneSystems Inc. Fundamentals Summary

How do 20/20 GeneSystems's earnings and revenue compare to its market cap?
TWTG fundamental statistics
Market cap	US$16.55m
Earnings (TTM)	US$0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is TWTG overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TWTG income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$0
Earnings	US$0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did TWTG perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2022/06/14 01:12
End of Day Share Price	2022/03/17 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

20/20 Biolabs, Inc. is covered by 1 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Michael Okunewitch	Maxim Group

20/20 Biolabs, Inc.OTCPK:TWTG Stock Report